FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Sjoerd Rodenhuis

Research Profile

Chemicals & Drugs

Procedures

Disorders

Concepts & Ideas

Genes & Molecular Sequences

Genes, ras

Co-author Network

Publications

TOP 3
Jorma J de Ronde; Ron Kerkhoven; Esther H Lips; Lennart Mulder; Marja Nieuwland; Sjoerd Rodenhuis; Gabe S Sonke; Andrew D Vincent; Marie-Jeanne T F D Vrancken Peeters; Jelle Wesseling; Lodewyk F A Wessels
SERPINA6, BEX1, AGTR1, SLC26A3, and LAPTM4B are markers of resistance to neoadjuvant chemotherapy in HER2-negative breast cancer.
Eva Giesen; Alet Mager; Sjoerd Rodenhuis; Harm van Tinteren; J Martijn Kerst
An alternative treatment regimen of advanced seminoma with carboplatin, etoposide, and bleomycin instead of cisplatin-based therapy.
Esther H Lips; Chad Livasy; Claudette E Loo; Rita A Mukhtar; Sjoerd Rodenhuis; E Shelley Hwang; Gabe S Sonke; Laura J van't Veer; Marie-Jeanne T F D Vrancken-Peeters; Jelle Wesseling; Christina Yau; Donald A Berry; Lisa A Carey; Jorma J de Ronde; Laura J Esserman
Lobular histology and response to neoadjuvant chemotherapy in invasive breast cancer.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Sjoerd Rodenhuis (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Jorma J de Ronde; Ron Kerkhoven; Esther H Lips; Lennart Mulder; Marja Nieuwland; Sjoerd Rodenhuis; Gabe S Sonke; Andrew D Vincent; Marie-Jeanne T F D Vrancken Peeters; Jelle Wesseling; Lodewyk F A Wessels
SERPINA6, BEX1, AGTR1, SLC26A3, and LAPTM4B are markers of resistance to neoadjuvant chemotherapy in HER2-negative breast cancer.
Breast cancer research and treatment 2013;137(1):213-23.
2013: Eva Giesen; Alet Mager; Sjoerd Rodenhuis; Harm van Tinteren; J Martijn Kerst
An alternative treatment regimen of advanced seminoma with carboplatin, etoposide, and bleomycin instead of cisplatin-based therapy.
Urologic oncology 2013;31(1):110-4.
2012: Esther H Lips; Chad Livasy; Claudette E Loo; Rita A Mukhtar; Sjoerd Rodenhuis; E Shelley Hwang; Gabe S Sonke; Laura J van't Veer; Marie-Jeanne T F D Vrancken-Peeters; Jelle Wesseling; Christina Yau; Donald A Berry; Lisa A Carey; Jorma J de Ronde; Laura J Esserman
Lobular histology and response to neoadjuvant chemotherapy in invasive breast cancer.
Breast cancer research and treatment 2012;136(1):35-43.
2012: Bas B Koolen; Sjoerd Rodenhuis; Renato A Valdés Olmos; Wouter V Vogel; Marie-Jeanne T F D Vrancken Peeters; Paula H M Elkhuizen; Emiel J Th Rutgers
Locoregional lymph node involvement on 18F-FDG PET/CT in breast cancer patients scheduled for neoadjuvant chemotherapy.
Breast cancer research and treatment 2012;135(1):231-40.
2011: Donald A Berry; Marco Bregni; Jean Caputo; R Charles Coombes; John P Crown; Elisabeth G E de Vries; William E Barlow; Russell L Basser; Jonas Bergh; ALESSANDRO MASSIMO GIANNI; Gabriel N Hortobagyi; Marcella M Johnson; Xiudong Lei; Robert C Leonard; Ulrike A Nitz; Paolo Pedrazzoli; William P Peters; Henri Roché; Sjoerd Rodenhuis; Martin S Tallman; Yutaka Tokuda; Naoto T Ueno; Axel R Zander; Taner Demirer
High-dose chemotherapy with autologous stem-cell support as adjuvant therapy in breast cancer: overview of 15 randomized trials.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(24):3214-23.
2011: Claudette E Loo; Marieke E Straver; Sjoerd Rodenhuis; Sara H Muller; Jelle Wesseling; Marie-Jeanne T F D Vrancken Peeters; Kenneth G A Gilhuijs
Magnetic resonance imaging response monitoring of breast cancer during neoadjuvant chemotherapy: relevance of breast cancer subtype.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(6):660-6.
2011: Esther H Lips; petra nederlof; Anne M M Oonk; Suvi P Savola; Marieke A Vollebergh; Jelle Wesseling; Lodewyk F A Wessels; Alex L T Imholz; Nadja Laddach; Sjoerd Rodenhuis
Quantitative copy number analysis by Multiplex Ligation-dependent Probe Amplification (MLPA) of BRCA1-associated breast cancer regions identifies BRCAness.
Breast cancer research : BCR 2011;13(5):R107.
2010: M E Straver; E J Th Rutgers; Sjoerd Rodenhuis; Sabine C Linn; Claudette E Loo; Jelle Wesseling; Nicola S Russell; Hester S A Oldenburg; Ninja Antonini; M T F D Vrancken Peeters
The relevance of breast cancer subtypes in the outcome of neoadjuvant chemotherapy.
Annals of surgical oncology 2010;17(9):2411-8.
2010: Marieke E Straver; Annuska M Glas; Juliane Hannemann; Jelle Wesseling; Marc J van de Vijver; E J Th Rutgers; Marie-Jeanne T F D Vrancken Peeters; Harm van Tinteren; Laura J van't Veer; Sjoerd Rodenhuis
The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer.
Breast cancer research and treatment 2010;119(3):551-8.
2010: Stefan Sleijfer; Monia Ouali; Martine Van Glabbeke; Anders Krarup-Hansen; Sjoerd Rodenhuis; Axel Le Cesne; Pancras C W Hogendoorn; Jaap Verweij; Jean-Yves Blay
Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG).
European journal of cancer (Oxford, England : 1990) 2010;46(1):72-83.
2010: Jorma J de Ronde; Juliane Hannemann; Hans Halfwerk; Lennart Mulder; Marieke E Straver; Marie-Jeanne T F D Vrancken Peeters; Jelle Wesseling; Marc J van de Vijver; Lodewyk F A Wessels; Sjoerd Rodenhuis
Concordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy response.
Breast cancer research and treatment 2010;119(1):119-26.
2009: M E Straver; E J Th Rutgers; Nicola S Russell; Hester S A Oldenburg; Sjoerd Rodenhuis; Jelle Wesseling; A Vincent; M T F D Vrancken Peeters
Towards rational axillary treatment in relation to neoadjuvant therapy in breast cancer.
European journal of cancer (Oxford, England : 1990) 2009;45(13):2284-92.
2009: Corine Ekhart; Sjoerd Rodenhuis; Jan H M Schellens; Jos H Beijnen; Alwin D R Huitema
Carboplatin dosing in overweight and obese patients with normal renal function, does weight matter?
Cancer chemotherapy and pharmacology 2009;64(1):115-22.
2009: Corine Ekhart; Sjoerd Rodenhuis; Jos H Beijnen; Alwin D R Huitema
Pharmacokinetics of cyclophosphamide and thiotepa in a conventional fractionated high-dose regimen compared with a novel simplified unfractionated regimen.
Therapeutic drug monitoring 2009;31(1):95-103.
2009: Corine Ekhart; Sjoerd Rodenhuis; Paul H M Smits; Jos H Beijnen; Alwin D R Huitema
An overview of the relations between polymorphisms in drug metabolising enzymes and drug transporters and survival after cancer drug treatment.
Cancer treatment reviews 2009;35(1):18-31.
2009: Corine Ekhart; Valerie D Doodeman; Sjoerd Rodenhuis; Paul H M Smits; Jos H Beijnen; Alwin D R Huitema
Polymorphisms of drug-metabolizing enzymes (GST, CYP2B6 and CYP3A) affect the pharmacokinetics of thiotepa and tepa.
British journal of clinical pharmacology 2009;67(1):50-60.
2009: Corine Ekhart; J Martijn Kerst; Sjoerd Rodenhuis; Jos H Beijnen; Alwin D R Huitema
Altered cyclophosphamide and thiotepa pharmacokinetics in a patient with moderate renal insufficiency.
Cancer chemotherapy and pharmacology 2009;63(2):375-9.
2008: Claudette E Loo; H Jelle Teertstra; Sjoerd Rodenhuis; Marc J van de Vijver; Juliane Hannemann; Saar H Muller; Marie-Jeanne Vrancken Peeters; Kenneth G A Gilhuijs
Dynamic contrast-enhanced MRI for prediction of breast cancer response to neoadjuvant chemotherapy: initial results.
AJR. American journal of roentgenology 2008;191(5):1331-8.
2008: Corine Ekhart; Sjoerd Rodenhuis; Paul H M Smits; Jos H Beijnen; Alwin D R Huitema
Relations between polymorphisms in drug-metabolising enzymes and toxicity of chemotherapy with cyclophosphamide, thiotepa and carboplatin.
Pharmacogenetics and genomics 2008;18(11):1009-15.
2008: Corine Ekhart; Valerie D Doodeman; Sjoerd Rodenhuis; Paul H M Smits; Jos H Beijnen; Alwin D R Huitema
Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and ALDH3A1) on the pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide.
Pharmacogenetics and genomics 2008;18(6):515-23.
2008: Marie-Christine W Gast; Harm van Tinteren; Marijke Bontenbal; René Q G C M van Hoesel; Marianne A Nooij; Sjoerd Rodenhuis; Paul N Span; Vivianne C G Tjan-Heijnen; Elisabeth G E de Vries; Nathan Harris; Jos W R Twisk; Jan H M Schellens; Jos H Beijnen
Haptoglobin phenotype is not a predictor of recurrence free survival in high-risk primary breast cancer patients.
BMC cancer 2008;8():389.
2007: Ciska Buijs; Sjoerd Rodenhuis; Caroline M Seynaeve; Q G C M van Hoesel; ELSKEN VAN DER WALL; Wim J M Smit; Marianne A Nooij; Emile E Voest; Pierre Hupperets; Elisabeth M TenVergert; Harm van Tinteren; P H B Willemse; Marian J E Mourits; Neil K Aaronson; Wendy J Post; Elisabeth G E de Vries
Prospective study of long-term impact of adjuvant high-dose and conventional-dose chemotherapy on health-related quality of life.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(34):5403-9.
2007: Jolien M Bueno-de-Mesquita; Wim H van Harten; Valesca P Retel; Laura J van't Veer; Frits S A M van Dam; Kim Karsenberg; Kirsten F L Douma; Harm van Tinteren; Johannes L Peterse; Jelle Wesseling; Tin S Wu; Douwe Atsma; E J Th Rutgers; Guido Brink; Arno N Floore; Annuska M Glas; R M H Roumen; Frank E Bellot; Cees van Krimpen; Sjoerd Rodenhuis; Marc J van de Vijver; Sabine C Linn
Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER).
The lancet oncology 2007;8(12):1079-87.
2007: Paul Lorigan; Jaap Verweij; Zsuzsa Papai; Sjoerd Rodenhuis; Axel Le Cesne; Michael G Leahy; John A Radford; Martine Van Glabbeke; Anne Kirkpatrick; Pancras Hogendoorn; Jean-Yves Blay
Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(21):3144-50.
2007: Corine Ekhart; Abadi Gebretensae; Hilde Rosing; Sjoerd Rodenhuis; Jos H Beijnen; Alwin D R Huitema
Simultaneous quantification of cyclophosphamide and its active metabolite 4-hydroxycyclophosphamide in human plasma by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry (LC-MS/MS).
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2007;854(1-2):345-9.
2007: Stephan A Veltkamp; Jetske M Meerum Terwogt; michel van den heuvel; Hester H van Boven; Jan H M Schellens; Sjoerd Rodenhuis
Severe pulmonary toxicity in patients with leiomyosarcoma after treatment with gemcitabine and docetaxel.
Investigational new drugs 2007;25(3):279-81.
2006: Juliane Hannemann; Petra M P Kristel; Harm van Tinteren; Marijke Bontenbal; Q G C M van Hoesel; W M Smit; Marianne A Nooij; Emile E Voest; ELSKEN VAN DER WALL; Pierre Hupperets; E G E de Vries; Sjoerd Rodenhuis; Marc J van de Vijver
Molecular subtypes of breast cancer and amplification of topoisomerase II alpha: predictive role in dose intensive adjuvant chemotherapy.
British journal of cancer 2006;95(10):1334-41.
2006: Corine Ekhart; Milly E De Jonge; Alwin D R Huitema; Jan H M Schellens; Sjoerd Rodenhuis; Jos H Beijnen
Flat dosing of carboplatin is justified in adult patients with normal renal function.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(21):6502-8.
2006: Milly E De Jonge; Alwin D R Huitema; Jos H Beijnen; Sjoerd Rodenhuis
High exposures to bioactivated cyclophosphamide are related to the occurrence of veno-occlusive disease of the liver following high-dose chemotherapy.
British journal of cancer 2006;94(9):1226-30.
2006: Sjoerd Rodenhuis; Marijke Bontenbal; Q G C M van Hoesel; W M Smit; Marianne A Nooij; Emile E Voest; ELSKEN VAN DER WALL; Pierre Hupperets; Harm van Tinteren; Johannes L Peterse; Marc J van de Vijver; E G E de Vries
Efficacy of high-dose alkylating chemotherapy in HER2/neu-negative breast cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2006;17(4):588-96.
2005: Milly E De Jonge; Alwin D R Huitema; Selma M Van Dam; Sjoerd Rodenhuis; Jos H Beijnen
Population pharmacokinetics of cyclophosphamide and its metabolites 4-hydroxycyclophosphamide, 2-dechloroethylcyclophosphamide, and phosphoramide mustard in a high-dose combination with Thiotepa and Carboplatin.
Therapeutic drug monitoring 2005;27(6):756-65.
2005: Peter Nieboer; Ciska Buijs; Sjoerd Rodenhuis; Caroline Seynaeve; Louk V A M Beex; ELSKEN VAN DER WALL; Dick J Richel; Marianne A Nooij; Emile E Voest; Pierre Hupperets; Nanno H Mulder; Winette T A van der Graaf; Elisabeth M TenVergert; Harm van Tinteren; Elisabeth G E de Vries
Fatigue and relating factors in high-risk breast cancer patients treated with adjuvant standard or high-dose chemotherapy: a longitudinal study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(33):8296-304.
2005: Milly E De Jonge; Alwin D R Huitema; Marjo J Holtkamp; Selma M Van Dam; Jos H Beijnen; Sjoerd Rodenhuis
Aprepitant inhibits cyclophosphamide bioactivation and thiotepa metabolism.
Cancer chemotherapy and pharmacology 2005;56(4):370-8.
2005: Milly E De Jonge; Alwin D R Huitema; Sjoerd Rodenhuis; Jos H Beijnen
Sparse sampling design for therapeutic drug monitoring of sequentially administered cyclophosphamide, thiotepa, and carboplatin (CTC).
Therapeutic drug monitoring 2005;27(3):393-402.
2005: Juliane Hannemann; Hendrika M Oosterkamp; Cathy A J Bosch; Arno Velds; Lodewyk F A Wessels; Claudette Loo; E J Th Rutgers; Sjoerd Rodenhuis; Marc J van de Vijver
Changes in gene expression associated with response to neoadjuvant chemotherapy in breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(15):3331-42.
2005: Milly E De Jonge; Alwin D R Huitema; Selma M Van Dam; Jos H Beijnen; Sjoerd Rodenhuis
Significant induction of cyclophosphamide and thiotepa metabolism by phenytoin.
Cancer chemotherapy and pharmacology 2005;55(5):507-10.
2005: Milly E De Jonge; Alwin D R Huitema; Jan Hm Schellens; Sjoerd Rodenhuis; Jos H Beijnen
Population pharmacokinetics of orally administered paclitaxel formulated in Cremophor EL.
British journal of clinical pharmacology 2005;59(3):325-34.
2005: Milly E De Jonge; Alwin D R Huitema; Selma M Van Dam; Sjoerd Rodenhuis; Jos H Beijnen
Effects of co-medicated drugs on cyclophosphamide bioactivation in human liver microsomes.
Anti-cancer drugs 2005;16(3):331-6.
2005: Milly E De Jonge; Alwin D R Huitema; Sjoerd Rodenhuis; Jos H Beijnen
Clinical pharmacokinetics of cyclophosphamide.
Clinical pharmacokinetics 2005;44(11):1135-64.
2005: Milly E De Jonge; Alwin D R Huitema; Annemarie C Tukker; Selma M Van Dam; Sjoerd Rodenhuis; Jos H Beijnen
Accuracy, feasibility, and clinical impact of prospective Bayesian pharmacokinetically guided dosing of cyclophosphamide, thiotepa, and carboplatin in high-dose chemotherapy.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(1):273-83.
2005: Milly E De Jonge; Alwin D R Huitema; Jan H M Schellens; Sjoerd Rodenhuis; Jos H Beijnen
Individualised cancer chemotherapy: strategies and performance of prospective studies on therapeutic drug monitoring with dose adaptation: a review.
Clinical pharmacokinetics 2005;44(2):147-73.
2005: Sjoerd Rodenhuis
Is high-dose chemotherapy dead?
European journal of cancer (Oxford, England : 1990) 2005;41(1):9-11.
2004: Ian F Faneyte; Johannes L Peterse; Harm van Tinteren; Corina Pronk; Marijke Bontenbal; Louk V A M Beex; ELSKEN VAN DER WALL; Dick J Richel; Marianne A Nooij; Emile E Voest; Pierre Hupperets; Elisabeth M Ten Vergert; Elisabeth G E de Vries; Sjoerd Rodenhuis; Marc J van de Vijver
Predicting early failure after adjuvant chemotherapy in high-risk breast cancer patients with extensive lymph node involvement.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(13):4457-63.
2004: Milly E De Jonge; Alwin D R Huitema; Sjoerd Rodenhuis; Jos H Beijnen
Integrated Population Pharmacokinetic Model of both cyclophosphamide and thiotepa suggesting a mutual drug-drug interaction.
Journal of pharmacokinetics and pharmacodynamics 2004;31(2):135-56.
2004: Milly E De Jonge; Selma M Van Dam; Michel J X Hillebrand; Hilde Rosing; Alwin D R Huitema; Sjoerd Rodenhuis; Jos H Beijnen
Simultaneous quantification of cyclophosphamide, 4-hydroxycyclophosphamide, N,N',N"-triethylenethiophosphoramide (thiotepa) and N,N',N"-triethylenephosphoramide (tepa) in human plasma by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry.
Journal of mass spectrometry : JMS 2004;39(3):262-71.
2003: Sjoerd Rodenhuis; Marijke Bontenbal; Louk V A M Beex; John Wagstaff; Dick J Richel; Marianne A Nooij; Emile E Voest; Pierre Hupperets; Harm van Tinteren; Hans L Peterse; Elisabeth M TenVergert; Elisabeth G E de Vries
High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer.
The New England journal of medicine 2003;349(1):7-16.
2003: JG Schrama; Marjo J Holtkamp; Joke W Baars; Jan H Schornagel; Sjoerd Rodenhuis
Toxicity of the high-dose chemotherapy CTC regimen (cyclophosphamide, thiotepa, carboplatin): the Netherlands Cancer Institute experience.
British journal of cancer 2003;88(12):1831-8.
2003: Milly E De Jonge; Ron A A Mathôt; Selma M Van Dam; Sjoerd Rodenhuis; Jos H Beijnen
Sorption of thiotepa to polyurethane catheter causes falsely elevated plasma levels.
Therapeutic drug monitoring 2003;25(3):261-3.
2003: JG Schrama; M M de Boer; Joke W Baars; Jan H Schornagel; Sjoerd Rodenhuis
Palliative chemotherapy after failure of high-dose chemotherapy in breast cancer--toxicity and efficacy.
Anticancer research 2003;23(3C):2795-800.
2003: Britta Weigelt; Astrid J Bosma; Augustinus A M Hart; Sjoerd Rodenhuis; Laura J van 't Veer
Marker genes for circulating tumour cells predict survival in metastasized breast cancer patients.
British journal of cancer 2003;88(7):1091-4.
2003: Ian F Faneyte; JG Schrama; Johannes L Peterse; P L Remijnse; Sjoerd Rodenhuis; Marc J van de Vijver
Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome.
British journal of cancer 2003;88(3):406-12.
2002: Marc J van de Vijver; Yudong D He; Laura J van't Veer; Hongyue Dai; Augustinus A M Hart; Dorien W Voskuil; George J Schreiber; Johannes L Peterse; Chris Roberts; Matthew J Marton; Mark Parrish; Douwe Atsma; Anke T Witteveen; Annuska M Glas; Leonie J M J Delahaye; Tony van der Velde; Harry Bartelink; Sjoerd Rodenhuis; Emiel T Rutgers; Stephen H Friend; René Bernards
A gene-expression signature as a predictor of survival in breast cancer.
The New England journal of medicine 2002;347(25):1999-2009.
2002: Milly E De Jonge; Ron A A Mathôt; Otilia Dalesio; Alwin D R Huitema; Sjoerd Rodenhuis; Jos H Beijnen
Relationship between irreversible alopecia and exposure to cyclophosphamide, thiotepa and carboplatin (CTC) in high-dose chemotherapy.
Bone marrow transplantation 2002;30(9):593-7.
2002: Milly E De Jonge; Ron A A Mathôt; Selma M Van Dam; Jos H Beijnen; Sjoerd Rodenhuis
Extremely high exposures in an obese patient receiving high-dose cyclophosphamide, thiotepa and carboplatin.
Cancer chemotherapy and pharmacology 2002;50(3):251-5.
2002: Sanne B Schagen; Martin J Muller; Willem Boogerd; R M Rosenbrand; D van Rhijn; Sjoerd Rodenhuis; Frits S A M van Dam
Late effects of adjuvant chemotherapy on cognitive function: a follow-up study in breast cancer patients.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2002;13(9):1387-97.
2002: Astrid J Bosma; Britta Weigelt; A Caro Lambrechts; Onno J H M Verhagen; Roelof Pruntel; Augustinus A M Hart; Sjoerd Rodenhuis; Laura J van 't Veer
Detection of circulating breast tumor cells by differential expression of marker genes.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(6):1871-7.
2002: JG Schrama; Ian F Faneyte; Jan H Schornagel; Joke W Baars; Johannes L Peterse; Marc J van de Vijver; Otilia Dalesio; Harm van Tinteren; E J Th Rutgers; D J Richelt; Sjoerd Rodenhuis
Randomized trial of high-dose chemotherapy and hematopoietic progenitor-cell support in operable breast cancer with extensive lymph node involvement: final analysis with 7 years of follow-up.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2002;13(5):689-98.
2002: Alwin D R Huitema; M Spaander; R A A Mathĵt; Matthijs M Tibben; Marjo J Holtkamp; Jos H Beijnen; Sjoerd Rodenhuis
Relationship between exposure and toxicity in high-dose chemotherapy with cyclophosphamide, thiotepa and carboplatin.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2002;13(3):374-84.
2002: Gijsbert C De Gast; Florry A Vyth-Dreese; Willem Nooijen; C J C van den Bogaard; Johan Sein; M M J Holtkamp; G A M Linthorst; Joke W Baars; Jan H Schornagel; Sjoerd Rodenhuis
Reinfusion of autologous lymphocytes with granulocyte-macrophage colony-stimulating factor induces rapid recovery of CD4+ and CD8+ T cells after high-dose chemotherapy for metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(1):58-64.
2001: Alwin D R Huitema; Ron A A Mathôt; Matthijs M Tibben; Sjoerd Rodenhuis; Jos H Beijnen
Validation of a therapeutic drug monitoring strategy for thiotepa in a high-dose chemotherapy regimen.
Therapeutic drug monitoring 2001;23(6):650-7.
2001: Thomas Kerbusch; R A Mathĵt; HJ Keizer; J Ouwerkerk; Sjoerd Rodenhuis; J H M Schellens; Jos H Beijnen
Population pharmacokinetics and exploratory pharmacodynamics of ifosfamide and metabolites after a 72-h continuous infusion in patients with soft tissue sarcoma.
European journal of clinical pharmacology 2001;57(6-7):467-77.
2001: JG Schrama; Joke W Baars; Marjo J Holtkamp; Jan H Schornagel; Jos H Beijnen; Sjoerd Rodenhuis
Phase II study of a multi-course high-dose chemotherapy regimen incorporating cyclophosphamide, thiotepa, and carboplatin in stage IV breast cancer.
Bone marrow transplantation 2001;28(2):173-80.
2001: MJ van Maanen; Alwin D R Huitema; Sjoerd Rodenhuis; Jos H Beijnen
Urinary excretion of thioTEPA and its metabolites in patients treated with high-dose cyclophosphamide, thioTEPA and carboplatin.
Anti-cancer drugs 2001;12(6):519-24.
2001: Alwin D R Huitema; C Reinders; Matthijs M Tibben; Sjoerd Rodenhuis; Jos H Beijnen
Sensitive gas chromatographic determination of the cyclophosphamide metabolite 2-dechloroethylcyclophosphamide in human plasma.
Journal of chromatography. B, Biomedical sciences and applications 2001;757(2):349-57.
2001: Alwin D R Huitema; Ron A A Mathôt; Matthijs M Tibben; Sjoerd Rodenhuis; Jos H Beijnen
A mechanism-based pharmacokinetic model for the cytochrome P450 drug-drug interaction between cyclophosphamide and thioTEPA and the autoinduction of cyclophosphamide.
Journal of pharmacokinetics and pharmacodynamics 2001;28(3):211-30.
2001: Sjoerd Rodenhuis
High-dose chemotherapy in breast cancer--interpretation of the randomized trials.
Anti-cancer drugs 2001;12(2):85-8.
2001: Carlijn Voermans; ML Kooi; Sjoerd Rodenhuis; H van der Lelie; C Ellen van der Schoot; Winald Gerritsen
In vitro migratory capacity of CD34+ cells is related to hematopoietic recovery after autologous stem cell transplantation.
Blood 2001;97(3):799-804.
2001: Alwin D R Huitema; Ron A A Mathôt; Matthijs M Tibben; J H M Schellens; Sjoerd Rodenhuis; Jos H Beijnen
Population pharmacokinetics of thioTEPA and its active metabolite TEPA in patients undergoing high-dose chemotherapy.
British journal of clinical pharmacology 2001;51(1):61-70.
2000: Alwin D R Huitema; Matthijs M Tibben; Thomas Kerbusch; J Jantina Kettenes-van den Bosch; Sjoerd Rodenhuis; Jos H Beijnen
Simple and selective determination of the cyclophosphamide metabolite phosphoramide mustard in human plasma using high-performance liquid chromatography.
Journal of chromatography. B, Biomedical sciences and applications 2000;745(2):345-55.
2000: Alwin D R Huitema; K D Smits; Ron A A Mathôt; J H M Schellens; Sjoerd Rodenhuis; Jos H Beijnen
The clinical pharmacology of alkylating agents in high-dose chemotherapy.
Anti-cancer drugs 2000;11(7):515-33.
2000: Axel Le Cesne; Ian Judson; D Crowther; Sjoerd Rodenhuis; HJ Keizer; Q G C M van Hoesel; Jean-Yves Blay; J Frisch; Martine Van Glabbeke; C Hermans; Allan van Oosterom; T Tursz; Jaap Verweij
Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(14):2676-84.
2000: Alwin D R Huitema; Ron A A Mathôt; Matthijs M Tibben; J H M Schellens; Sjoerd Rodenhuis; Jos H Beijnen
Validation of techniques for the prediction of carboplatin exposure: application of Bayesian methods.
Clinical pharmacology and therapeutics 2000;67(6):621-30.
2000: Sjoerd Rodenhuis; Alwin D R Huitema; Frits S A M van Dam; Elisabeth G E de Vries; Jos H Beijnen
High-dose chemotherapy with peripheral blood progenitor cell transplantation in the adjuvant treatment of breast cancer.
Cancer journal (Sudbury, Mass.) 2000;6 Suppl 2():S125-30.
2000: Alwin D R Huitema; Thomas Kerbusch; Matthijs M Tibben; Sjoerd Rodenhuis; Jos H Beijnen
Reduction of cyclophosphamide bioactivation by thioTEPA: critical sequence-dependency in high-dose chemotherapy regimens.
Cancer chemotherapy and pharmacology 2000;46(2):119-27.
2000: Anneke M Westermann; Ria Dubbelman; J P Baars; Wouter H Moolenaar; Jos H Beijnen; Sjoerd Rodenhuis
Feasibility and pharmacokinetics of intraperitoneal suramin in advanced malignancy.
Cancer chemotherapy and pharmacology 2000;46(1):57-62.
2000: Hilde Rosing; V Lustig; LJ van Warmerdam; manon huizing; Wim W ten Bokkel Huinink; J H M Schellens; Sjoerd Rodenhuis; A Bult; Jos H Beijnen
Pharmacokinetics and metabolism of docetaxel administered as a 1-h intravenous infusion.
Cancer chemotherapy and pharmacology 2000;45(3):213-8.
1999: Sjoerd Rodenhuis; Ronald de Wit; P H de Mulder; HJ Keizer; D T Sleijfer; R I Lalisang; P J Bakker; IA Mandjes; ML Kooi; Elisabeth G E de Vries
A multi-center prospective phase II study of high-dose chemotherapy in germ-cell cancer patients relapsing from complete remission.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1999;10(12):1467-73.
1999: MJ van Maanen; I M Tijhof; JM Damen; Cees Versluis; J J van den Bosch; albert heck; Sjoerd Rodenhuis; Jos H Beijnen
A search for new metabolites of N,N',N''-triethylenethiophosphoramide.
Cancer research 1999;59(18):4720-4.
1999: A Caro Lambrechts; Astrid J Bosma; S G Klaver; B Top; L Perebolte; L J van' t Veer; Sjoerd Rodenhuis
Comparison of immunocytochemistry, reverse transcriptase polymerase chain reaction, and nucleic acid sequence-based amplification for the detection of circulating breast cancer cells.
Breast cancer research and treatment 1999;56(3):219-31.
1999: Anneke M Westermann; M M J Holtkamp; G A Linthorst; L van Leeuwen; E J Willemse; W C van Dijk; Willem Nooijen; Joke W Baars; Jan H Schornagel; Sjoerd Rodenhuis
At home management of aplastic phase following high-dose chemotherapy with stem-cell rescue for hematological and non-hematological malignancies.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1999;10(5):511-7.
1999: Alwin D R Huitema; M M J Holtkamp; Matthijs M Tibben; Sjoerd Rodenhuis; Jos H Beijnen
Sampling technique from central venous catheters proves critical for pharmacokinetic studies.
Therapeutic drug monitoring 1999;21(1):102-4.
1999: R van Gijn; Wim W ten Bokkel Huinink; Sjoerd Rodenhuis; Jan B Vermorken; Olaf van Tellingen; Hilde Rosing; LJ van Warmerdam; Jos H Beijnen
Topoisomerase I/II inhibitor intoplicine administered as a 24 h infusion: phase I and pharmacologic study.
Anti-cancer drugs 1999;10(1):17-23.
1999: VR Panday; LJ van Warmerdam; manon huizing; Sjoerd Rodenhuis; J H M Schellens; Jos H Beijnen
A single 24-hour plasma sample does not predict the carboplatin AUC from carboplatin-paclitaxel combinations or from a high-dose carboplatin-thiotepa-cyclophosphamide regimen.
Cancer chemotherapy and pharmacology 1999;43(5):435-8.
1998: A Caro Lambrechts; Laura J van 't Veer; Sjoerd Rodenhuis
The detection of minimal numbers of contaminating epithelial tumor cells in blood or bone marrow: use, limitations and future of RNA-based methods.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1998;9(12):1269-76.
1998: RJ van Maanen; Ronald D van Ooijen; JW Zwikker; Alwin D R Huitema; Sjoerd Rodenhuis; Jos H Beijnen
Determination of N,N',N"-triethylenethiophosphoramide and its active metabolite N,N',N"-triethylenephosphoramide in plasma and urine using capillary gas chromatography.
Journal of chromatography. B, Biomedical sciences and applications 1998;719(1-2):103-12.
1998: Alwin D R Huitema; Matthijs M Tibben; Thomas Kerbusch; JW Zwikker; Sjoerd Rodenhuis; Jos H Beijnen
Simultaneous determination of N,N',N"-triethylenethiophosphoramide, cyclophosphamide and some of their metabolites in plasma using capillary gas chromatography.
Journal of chromatography. B, Biomedical sciences and applications 1998;716(1-2):177-86.
1998: Sjoerd Rodenhuis; Dick J Richel; ELSKEN VAN DER WALL; Jan H Schornagel; Joke W Baars; C C Koning; Johannes L Peterse; Jacques H Borger; Willem Nooijen; Roel Bakx; Otilia Dalesio; E J Th Rutgers
Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement.
Lancet 1998;352(9127):515-21.
1998: Anneke M Westermann; E Havik; Friso R Postma; Jos H Beijnen; Otilia Dalesio; Wouter H Moolenaar; Sjoerd Rodenhuis
Malignant effusions contain lysophosphatidic acid (LPA)-like activity.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1998;9(4):437-42.
1998: Frits S A M van Dam; Sanne B Schagen; Martin J Muller; Willem Boogerd; E vd Wall; M E Droogleever Fortuyn; Sjoerd Rodenhuis
Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy.
Journal of the National Cancer Institute 1998;90(3):210-8.
1997: M S de Lange; B Top; C Lambrechts; R A Maas; Hans L Peterse; Wolter J Mooi; Laura J van 't Veer; Sjoerd Rodenhuis
A method to monitor mRNA levels in human breast tumor cells obtained by fine-needle aspiration.
Diagnostic molecular pathology : the American journal of surgical pathology, part B 1997;6(6):353-60.
1997: Wim W ten Bokkel Huinink; V Lustig; Ria Dubbelman; A Hiemstra; Sjoerd Rodenhuis
Docetaxel alternating with epirubicin and cyclophosphamide: a feasibility study in breast cancer patients.
European journal of cancer (Oxford, England : 1990) 1997;33 Suppl 7():S23-5.
1997: Anneke M Westermann; Ria Dubbelman; Wouter H Moolenaar; Jos H Beijnen; Sjoerd Rodenhuis
Successful intraperitoneal suramin treatment of peritoneal mesothelioma.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1997;8(8):801-2.
1997: manon huizing; LJ van Warmerdam; Hilde Rosing; M C Schaefers; A Lai; TJ Helmerhorst; Cindy Veenhof; M J Birkhofer; Sjoerd Rodenhuis; Jos H Beijnen; Wim W ten Bokkel Huinink
Phase I and pharmacologic study of the combination paclitaxel and carboplatin as first-line chemotherapy in stage III and IV ovarian cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(5):1953-64.
1997: Wim W ten Bokkel Huinink; LJ van Warmerdam; TJ Helmerhorst; M C Schaefers; Jos H Beijnen; Sjoerd Rodenhuis
Phase II study of the combination carboplatin and paclitaxel in patients with ovarian cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1997;8(4):351-4.
1997: Anneke M Westermann; Jos H Beijnen; Wouter H Moolenaar; Sjoerd Rodenhuis
Growth factors in human ovarian cancer.
Cancer treatment reviews 1997;23(2):113-31.
1997: Wim W ten Bokkel Huinink; Cindy Veenhof; manon huizing; Sjoerd Rodenhuis; TJ Helmerhorst; Ria Dubbelman; Otilia Dalesio; Jos H Beijnen; B Winograd
Carboplatin and paclitaxel in patients with advanced ovarian cancer: a dose-finding study.
Seminars in oncology 1997;24(1 Suppl 2):S2-31-S2-33.
1997: Sjoerd Rodenhuis; Lucie Boerrigter; B Top; R J Slebos; Wolter J Mooi; Laura J van't Veer; nico van zandwijk
Mutational activation of the K-ras oncogene and the effect of chemotherapy in advanced adenocarcinoma of the lung: a prospective study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(1):285-91.
1996: Joke W Baars; M J Holtkamp; W J Nooyen; E V Walll; Anje A Te Velde; Otilia Dalesio; Ineke Slaper-Cortenbach; E V Schoot; Dick J Richel; Winald Gerritsen; Jan H Schornagel; Sjoerd Rodenhuis
Mobilisation of blood progenitor cells with ifosfamide and etoposide (VP-16) in combination with recombinant human G-CSF (Filgrastim) in patients with malignant lymphomas or solid tumours.
Anticancer research 1996;16(5B):3089-95.
1996: ELSKEN VAN DER WALL; C C Schaake-Koning; nico van zandwijk; Joke W Baars; Jan H Schornagel; Dick J Richel; E J Th Rutgers; Jacques H Borger; Jos H Beijnen; Sjoerd Rodenhuis
The toxicity of radiotherapy following high-dose chemotherapy with peripheral blood stem cell support in high-risk breast cancer: a preliminary analysis.
European journal of cancer (Oxford, England : 1990) 1996;32A(9):1490-7.
1996: ELSKEN VAN DER WALL; E J Th Rutgers; M J Holtkamp; Joke W Baars; Jan H Schornagel; Johannes L Peterse; Jos H Beijnen; Sjoerd Rodenhuis
Efficacy of up-front 5-fluorouracil-epidoxorubicin-cyclophosphamide (FEC) chemotherapy with an increased dose of epidoxorubicin in high-risk breast cancer patients.
British journal of cancer 1996;73(9):1080-5.
1996: Sjoerd Rodenhuis; Anneke M Westermann; M J Holtkamp; Willem Nooijen; Joke W Baars; ELSKEN VAN DER WALL; Ineke Slaper-Cortenbach; Jan H Schornagel
Feasibility of multiple courses of high-dose cyclophosphamide, thiotepa, and carboplatin for breast cancer or germ cell cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(5):1473-83.
1996: LJ van Warmerdam; Sjoerd Rodenhuis; ELSKEN VAN DER WALL; R A Maes; Jos H Beijnen
Pharmacokinetics and pharmacodynamics of carboplatin administered in a high-dose combination regimen with thiotepa, cyclophosphamide and peripheral stem cell support.
British journal of cancer 1996;73(8):979-84.
1996: Olaf van Tellingen; M T Kuck; L T Vlasveld; Sjoerd Rodenhuis; Willem Nooijen; Jos H Beijnen
Unchanged pharmacokinetics of etoposide given by intra-arterial hepatic infusion as compared with i.v. infusion.
Cancer chemotherapy and pharmacology 1996;38(4):387-90.
1996: LJ van Warmerdam; Geert-Jan Creemers; Sjoerd Rodenhuis; Hilde Rosing; MM de Boer-Dennert; J H M Schellens; Wim W ten Bokkel Huinink; brian e davies; R A Maes; Jaap Verweij; Jos H Beijnen
Pharmacokinetics and pharmacodynamics of topotecan given on a daily-times-five schedule in phase II clinical trials using a limited-sampling procedure.
Cancer chemotherapy and pharmacology 1996;38(3):254-60.
1996: LJ van Warmerdam; Sjoerd Rodenhuis; Wim W ten Bokkel Huinink; R A Maes; Jos H Beijnen
Evaluation of formulas using the serum creatinine level to calculate the optimal dosage of carboplatin.
Cancer chemotherapy and pharmacology 1996;37(3):266-70.
1995: Mikael E Craanen; P Blok; B Top; Lucie Boerrigter; W Dekker; G Johan A Offerhaus; G N J Tytgat; Sjoerd Rodenhuis
Absence of ras gene mutations in early gastric carcinomas.
Gut 1995;37(6):758-62.
1995: LJ van Warmerdam; Olaf van Tellingen; Wim W ten Bokkel Huinink; Sjoerd Rodenhuis; R A Maes; J H Bijnen
Monitoring carboplatin concentrations in saliva: a replacement for plasma ultrafiltrate measurements?
Therapeutic drug monitoring 1995;17(5):465-70.
1995: M W Dercksen; Sjoerd Rodenhuis; M K Dirkson; Wim Schaasberg; Joke W Baars; ELSKEN VAN DER WALL; Ineke Slaper-Cortenbach; HERBERT PINEDO; A E Von dem Borne; C Ellen van der Schoot
Subsets of CD34+ cells and rapid hematopoietic recovery after peripheral-blood stem-cell transplantation.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(8):1922-32.
1995: LJ van Warmerdam; Wim W ten Bokkel Huinink; Sjoerd Rodenhuis; I Koier; brian e davies; Hilde Rosing; R A Maes; Jos H Beijnen
Phase I clinical and pharmacokinetic study of topotecan administered by a 24-hour continuous infusion.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(7):1768-76.
1995: M W Dercksen; Winald Gerritsen; Sjoerd Rodenhuis; M K Dirkson; Ineke Slaper-Cortenbach; Wim Schaasberg; HERBERT PINEDO; A E von dem Borne; C Ellen van der Schoot
Expression of adhesion molecules on CD34+ cells: CD34+ L-selectin+ cells predict a rapid platelet recovery after peripheral blood stem cell transplantation.
Blood 1995;85(11):3313-9.
1995: B Top; Wolter J Mooi; S G Klaver; Lucie Boerrigter; P Wisman; H R Elbers; S Visser; Sjoerd Rodenhuis
Comparative analysis of p53 gene mutations and protein accumulation in human non-small-cell lung cancer.
International journal of cancer. Journal international du cancer 1995;64(2):83-91.
1995: ELSKEN VAN DER WALL; Willem Nooijen; Joke W Baars; M J Holtkamp; J H Schorangel; Dick J Richel; E J Th Rutgers; Ineke Slaper-Cortenbach; C Ellen van der Schoot; Sjoerd Rodenhuis
High-dose carboplatin, thiotepa and cyclophosphamide (CTC) with peripheral blood stem cell support in the adjuvant therapy of high-risk breast cancer: a practical approach.
British journal of cancer 1995;71(4):857-62.
1995: ELSKEN VAN DER WALL; Jos H Beijnen; Sjoerd Rodenhuis
High-dose chemotherapy regimens for solid tumors.
Cancer treatment reviews 1995;21(2):105-32.
1995: R A Olie; Leendert H J Looijenga; Lucie Boerrigter; B Top; Sjoerd Rodenhuis; An Langeveld; M P Mulder; J Wolter Oosterhuis
N- and KRAS mutations in primary testicular germ cell tumors: incidence and possible biological implications.
Genes, chromosomes & cancer 1995;12(2):110-6.
1995: LJ van Warmerdam; Sjoerd Rodenhuis; Wim W ten Bokkel Huinink; R A Maes; Jos H Beijnen
The use of the Calvert formula to determine the optimal carboplatin dosage.
Journal of cancer research and clinical oncology 1995;121(8):478-86.
1995: Sjoerd Rodenhuis; ELSKEN VAN DER WALL; Wim W ten Bokkel Huinink; Jan H Schornagel; Dick J Richel; L T Vlasveld
Pilot study of a high-dose carboplatin-based salvage strategy for relapsing or refractory germ cell cancer.
Cancer investigation 1995;13(4):355-62.
1994: ELSKEN VAN DER WALL; Dick J Richel; M J Holtkamp; Ineke Slaper-Cortenbach; C Ellen van der Schoot; Otilia Dalesio; Willem Nooijen; Jan H Schornagel; Sjoerd Rodenhuis
Bone marrow reconstitution after high-dose chemotherapy and autologous peripheral blood progenitor cell transplantation: effect of graft size.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1994;5(9):795-802.
1994: Henk van Halteren; B Top; Wolter J Mooi; Alfons J M Balm; Sjoerd Rodenhuis
Association of H-ras mutations with adenocarcinomas of the parotid gland.
International journal of cancer. Journal international du cancer 1994;57(3):362-4.
1994: L T Vlasveld; Sjoerd Rodenhuis; E J Th Rutgers; A C Dubbelman; A M Hilton; Diane Batchelor; E M Rankin
Catheter-related complications in 52 patients treated with continuous infusion of low dose recombinant interleukin-2 via an implanted central venous catheter.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 1994;20(2):122-9.
1994: J A Kern; RJ Slebos; B Top; Sjoerd Rodenhuis; Donna J Lager; Robert A Robinson; D Weiner; D A Schwartz
C-erbB-2 expression and codon 12 K-ras mutations both predict shortened survival for patients with pulmonary adenocarcinomas.
The Journal of clinical investigation 1994;93(2):516-20.
1994: LJ van Warmerdam; Sjoerd Rodenhuis; Olaf van Tellingen; R A Maes; Jos H Beijnen
Validation of a limited sampling model for carboplatin in a high-dose chemotherapy combination.
Cancer chemotherapy and pharmacology 1994;35(2):179-81.
1994: J H Sips; Olaf van Tellingen; Willem Nooijen; Sjoerd Rodenhuis; W J Ten Bokkel Huinink; Jos H Beijnen
The pharmacokinetics of reduced folates after intraperitoneal and intravenous administration of racemic [6S,R]-folinic acid.
Cancer chemotherapy and pharmacology 1994;35(2):144-8.
1993: Dick J Richel; ELSKEN VAN DER WALL; J Slaper; E Van der Schoot; Sjoerd Rodenhuis
Peripheral blood stem cell (PBSC) mobilization and transplantation (PSCT) in patients with malignant lymphomas and solid tumors.
The International journal of artificial organs 1993;16 Suppl 5():71-5.
1993: ELSKEN VAN DER WALL; Dick J Richel; Y H Kusumanto; E J Th Rutgers; Jan H Schornagel; C C Schaake-Koning; Johannes L Peterse; Sjoerd Rodenhuis
Feasibility study of FEC-chemotherapy with dose-intensive epirubicin as initial treatment in high-risk breast cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1993;4(9):791-2.
1993: L T Vlasveld; A Hekman; Florry A Vyth-Dreese; E M Rankin; J G Scharenberg; A C Voordouw; J J Sein; T A Dellemijn; Sjoerd Rodenhuis; Cornelis J M Melief
A phase I study of prolonged continuous infusion of low dose recombinant interleukin-2 in melanoma and renal cell cancer. Part II: Immunological aspects.
British journal of cancer 1993;68(3):559-67.
1993: Sjoerd Rodenhuis; L G van't Hek; L T Vlasveld; R Kröger; Ria Dubbelman; R G van Tol
Central venous catheter associated thrombosis of major veins: thrombolytic treatment with recombinant tissue plasminogen activator.
Thorax 1993;48(5):558-9.
1993: Babs G Taal; Wim W ten Bokkel Huinink; Sjoerd Rodenhuis
Combination chemotherapy with tauromustine (TCNU), 5-fluorouracil and leucovorin in advanced colorectal carcinoma: a dose-finding study.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1993;4(1):81-2.
1992: Sjoerd Rodenhuis; Joke W Baars; Jan H Schornagel; L T Vlasveld; IA Mandjes; HERBERT PINEDO; Dick J Richel
Feasibility and toxicity study of a high-dose chemotherapy regimen for autotransplantation incorporating carboplatin, cyclophosphamide and thiotepa.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1992;3(10):855-60.
1992: Wim W ten Bokkel Huinink; M Clavel; Sjoerd Rodenhuis; J P Guastalla; H R Franklin; J J Koier; T Vlasveld; Otilia Dalesio; H van Tinteren; HERBERT PINEDO
Mitoxantrone and GM-CSF: a phase I study with an escalated dose of mitoxantrone in breast cancer.
Pathologie-biologie 1992;39(9):962.
1992: Sjoerd Rodenhuis; L T Vlasveld; Ria Dubbelman; R Roodbergen; Jan H Schornagel; Jantien Wanders; S P Israels; E Bais; Wim W ten Bokkel Huinink; Dick J Richel
Feasibility study of high-dose carboplatin and etoposide in the salvage treatment of testicular cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1992;3(6):463-7.
1992: RJ Slebos; Lucie Boerrigter; S G Evers; P Wisman; Wolter J Mooi; Sjoerd Rodenhuis
A rapid and simple procedure for the routine detection of ras point mutations in formalin-fixed, paraffin-embedded tissues.
Diagnostic molecular pathology : the American journal of surgical pathology, part B 1992;1(2):136-41.
1992: L T Vlasveld; E M Rankin; A Hekman; Sjoerd Rodenhuis; Jos H Beijnen; A M Hilton; A C Dubbelman; Florry A Vyth-Dreese; Cornelis J M Melief
A phase I study of prolonged continuous infusion of low dose recombinant interleukin-2 in melanoma and renal cell cancer. Part I: Clinical aspects.
British journal of cancer 1992;65(5):744-50.
1992: Sjoerd Rodenhuis; RJ Slebos
Clinical significance of ras oncogene activation in human lung cancer.
Cancer research 1992;52(9 Suppl):2665s-2669s.
1992: Jos H Beijnen; L T Vlasveld; Jantien Wanders; Wim W ten Bokkel Huinink; Sjoerd Rodenhuis
Effect of cisplatin-containing chemotherapy on lithium serum concentrations.
The Annals of pharmacotherapy 1992;26(4):488-90.
1992: L T Vlasveld; J F Delemarre; J H Beynen; Sjoerd Rodenhuis
Invasive aspergillosis complicated by subclavian artery occlusion and costal osteomyelitis after autologous bone marrow transplantation.
Thorax 1992;47(2):136-7.
1992: Wim W ten Bokkel Huinink; Otilia Dalesio; Sjoerd Rodenhuis; Ria Dubbelman; A Hilton; H Franklin; I Koier; H van Tinteren; M E L van der Burg; AT van Oosterom
Replacement of cisplatin with carboplatin in combination chemotherapy against ovarian cancer: long-term treatment results of a study of the Gynaecological Cancer Cooperative Group of the EORTC and experience at The Netherlands Cancer Institute.
Seminars in oncology 1992;19(1 Suppl 2):99-101.
1992: L T Vlasveld; Babs G Taal; B B Kroon; M P Gallee; Sjoerd Rodenhuis
Intestinal obstruction due to diffuse peritoneal fibrosis at 2 years after the successful treatment of malignant peritoneal mesothelioma with intraperitoneal mitoxantrone.
Cancer chemotherapy and pharmacology 1992;29(5):405-8.
1991: Joost Oudejans; RJ Slebos; Frans A N Zoetmulder; Wolter J Mooi; Sjoerd Rodenhuis
Differential activation of ras genes by point mutation in human colon cancer with metastases to either lung or liver.
International journal of cancer. Journal international du cancer 1991;49(6):875-9.
1991: RJ Slebos; Ralph Hruban; Otilia Dalesio; W J Mooi; G Johan A Offerhaus; Sjoerd Rodenhuis
Relationship between K-ras oncogene activation and smoking in adenocarcinoma of the human lung.
Journal of the National Cancer Institute 1991;83(14):1024-7.
1991: RJ Slebos; Gaston Habets; S G Evers; Wolter J Mooi; Sjoerd Rodenhuis
Allele-specific detection of K-ras oncogene expression in human non-small-cell lung carcinomas.
International journal of cancer. Journal international du cancer 1991;48(1):51-6.
1991: L T Vlasveld; M P Gallee; Sjoerd Rodenhuis; Babs G Taal
Intraperitoneal chemotherapy for malignant peritoneal mesothelioma.
European journal of cancer (Oxford, England : 1990) 1991;27(6):732-4.
1991: A Hekman; A Honselaar; W M Vuist; J J Sein; Sjoerd Rodenhuis; W W ten Bokkel Huinink; R Somers; P Rümke; Cornelis J M Melief
Initial experience with treatment of human B cell lymphoma with anti-CD19 monoclonal antibody.
Cancer immunology, immunotherapy : CII 1991;32(6):364-72.
1990: L T Vlasveld; J H Beynen; Willem Boogerd; Wim W ten Bokkel Huinink; Sjoerd Rodenhuis
Complete remission of brain metastases of ovarian cancer following high-dose carboplatin: a case report and pharmacokinetic study.
Cancer chemotherapy and pharmacology 1990;25(5):382-3.
1990: Jos H Beijnen; B R Smith; W J Keijer; R van Gijn; Wim W ten Bokkel Huinink; L T Vlasveld; Sjoerd Rodenhuis; Willy J M Underberg
High-performance liquid chromatographic analysis of the new antitumour drug SK&F 104864-A (NSC 609699) in plasma.
Journal of pharmaceutical and biomedical analysis 1990;8(8-12):789-94.
1989: RJ Slebos; Sjoerd Rodenhuis
The molecular genetics of human lung cancer.
The European respiratory journal : official journal of the European Society for Clinical Respiratory Physiology 1989;2(5):461-9.
1989: RJ Slebos; S G Evers; S S Wagenaar; Sjoerd Rodenhuis
Cellular protoonocogenes are infrequently amplified in untreated non-small cell lung cancer.
British journal of cancer 1989;59(1):76-80.
1988: Sjoerd Rodenhuis; RJ Slebos; A J Boot; S G Evers; Wolter J Mooi; S S Wagenaar; P C van Bodegom; J L Bos
Incidence and possible clinical significance of K-ras oncogene activation in adenocarcinoma of the human lung.
Cancer research 1988;48(20):5738-41.
1988: RJ Slebos; A de Graeff; nico van zandwijk; W J Mooi; J L Bos; Sjoerd Rodenhuis
Recurrent breast cancer and an adenocarcinoma of the lung occurring in one patient: c-myc oncogene amplification and K-ras codon 12 point mutation as tumour markers.
European journal of cancer & clinical oncology 1988;24(9):1529-30.
1988: A de Graeff; RJ Slebos; Sjoerd Rodenhuis
Resistance to cisplatin and analogues: mechanisms and potential clinical implications.
Cancer chemotherapy and pharmacology 1988;22(4):325-32.
1987: Sjoerd Rodenhuis; M L van de Wetering; Wolter J Mooi; S G Evers; nico van zandwijk; J L Bos
Mutational activation of the K-ras oncogene. A possible pathogenetic factor in adenocarcinoma of the lung.
The New England journal of medicine 1987;317(15):929-35.